Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

May 17, 2021

Primary Completion Date

November 15, 2021

Study Completion Date

December 3, 2021

Conditions
Factor VII DeficiencyGlanzmann ThrombastheniaHemophilia A With Inhibitor
Interventions
BIOLOGICAL

Coagulation Factor VIIa variant

Single intravenous dose and ascending doses of subcutaneous injection of MarzAA, followed by a fixed dose of MarzAA for the treatment of bleeding episodes

Trial Locations (20)

27858

East Carolina University, Greenville

48201

Children's Hospital of Michigan, Detroit

49805

Michigan State University Center for Bleeding Disorders & Clotting Disorders, East Lansing

60612

Rush University, Chicago

80045

University of Colorado Hemophilia and Thrombosis Center, Aurora

94143

University of California -San Francisco, San Francisco

95817

UC Davis Medical Center, Sacramento

Unknown

Mazumdar Shaw Medical Centre, Bengaluru

St. John's Medical College Hospital, Bengaluru

Amrita Institute of Medical Sciences and Research Centre, Kochi

K. J. Somaiya Hospital and Research Centre, Mumbai

Sahyadri Super Speciality Hospital, Pune

Careggi University Hospital, Florence

Center for Thrombosis and Haemorrhagic Diseases, Milan

Maggiore Polyclinic Hospital, IRCCS Ca' Granda, Milan

Children's Hospital BambiNo Gesù, IRCCS (PEDS), Roma

City of Health and Science of Turin, Turin

Territorial Clinical Hospital, Barnaul

National Medical Hematology Research Center under the Ministry of Healthcare of the Russian Federation, Moscow

Institute of Blood Pathology and Transfusion Medicine, Department of Surgery and Clinical Transfusiology, Lviv

Sponsors
All Listed Sponsors
lead

Catalyst Biosciences

INDUSTRY